Partner Dan Shores will serve as a panelist on the session "Litigation Watchlist: Breaking Down the Latest Disputes in mRNA, LNP, and ADC Patents" at American Conference Institute's (ACI) 4th Annual Forum on Advanced Therapeutics taking place March 25-26, 2026, in Boston, Massachusetts. Dan's session will take place on the second day of the conference, March 26.
Patent litigation remains one of the most closely watched dynamics in advanced therapeutics, with high-stakes disputes shaping the future of innovation, exclusivity, and commercialization. From ongoing battles over mRNA and lipid nanoparticle (LNP) technologies to the rising wave of litigation surrounding antibody-drug conjugates (ADCs), these cases reveal not only the value of platform technologies but also the pressure points where innovators are most vulnerable. This session will unpack the litigation landscape to clarify what’s really at stake — and what it means for the next wave of advanced medicines.
Discussion points include:
- mRNA and LNP litigation trends: Breaking down the core claims, defenses, and outcomes shaping platform IP battles
- ADCs in the spotlight: Why antibody-drug conjugates are becoming a new IP flashpoint and what disputes signal for innovators
- Freedom-to-operate risks: Practical considerations for companies navigating crowded patent spaces and overlapping claims
- Strategic implications: What ongoing disputes mean for licensing, collaborations, and portfolio-building in advanced therapeutics
ACI’s Forum on Advanced Therapeutics returns with a renewed focus on the dynamic forces shaping the future of RNA, cell and gene therapies, and regenerative medicine. Designed for professionals across legal, regulatory, scientific, and business functions, the event dives into the evolving landscape of policy, IP, funding, innovation, and commercialization.
To learn more about ACI's Annual Forum on Advanced Therapeutics, and to register, please visit the event website.
